New publication highlights unique properties of ati-2138, a potent and selective inhibitor of itk and jak3

- data generated to date support potential for aclaris' ati-2138 to impact several human inflammatory diseases - wayne, pa., feb. 12, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of aclaris therapeutics' ati-2138, a novel investigational covalent inhibitor of interleukin-2-inducible t cell kinase (itk) and janus kinase 3 (jak3) in development for the treatment of autoimmune and inflammatory diseases.
ACRS Ratings Summary
ACRS Quant Ranking